Regencell Bioscience (NASDAQ:RGC) Stock Price Up 7.1% – Still a Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) rose 7.1% during mid-day trading on Tuesday . The company traded as high as $12.00 and last traded at $11.2530. Approximately 156,350 shares were traded during trading, a decline of 44% from the average daily volume of 280,112 shares. The stock had previously closed at $10.51.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Regencell Bioscience Trading Up 6.0%

The stock’s 50 day moving average price is $24.88 and its 200 day moving average price is $25.80.

Regencell Bioscience (NASDAQ:RGC) last released its earnings results on Friday, May 8th. The company reported ($0.00) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Regencell Bioscience

Several institutional investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP acquired a new stake in shares of Regencell Bioscience in the fourth quarter worth $92,000. Amundi purchased a new stake in Regencell Bioscience during the 1st quarter worth $219,000. Hudson Bay Capital Management LP acquired a new stake in Regencell Bioscience in the 4th quarter valued at $275,000. Bank of America Corp DE increased its holdings in Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after purchasing an additional 17,143 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Regencell Bioscience in the third quarter valued at about $598,000. 0.13% of the stock is currently owned by hedge funds and other institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.